A Narrative Review of Pheochromocytoma in VHL

Main Article Content

Danilo Coco https://orcid.org/0000-0002-5839-1767
Silvana Leanza https://orcid.org/0000-0001-8672-7486


Von Hippel-Lindau, Pheochromocytoma, Genetic predisposition, Biochemical diagnosis


This systematic review aims to investigate the clinical presentation, diagnostic methods, and management strategies for pheochromocytoma in patients with von Hippel-Lindau (VHL) disease, an autosomal dominant disorder that predisposes individuals to the development of various tumors, including pheochromocytomas. Pheochromocytoma is a rare neuroendocrine tumor of the adrenal medulla that occurs sporadically or as part of an inherited syndrome. The incidence of pheochromocytoma in VHL patients is estimated to be between 10–20%, making it the second most common tumor associated with VHL. Early detection and management of pheochromocytoma in VHL patients are critical for patient outcomes, as these tumors can cause severe hypertension, cardiovascular complications, and death. This review highlights the importance of screening for pheochromocytoma in VHL patients and discusses the current diagnostic and management strategies to optimize patient care.

Abstract 95 | PDF Downloads 91 HTML Downloads 0 XML Downloads 1


1. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: Recommendations for clinical practice from the First International Symposium October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102. 10.1038/ncpendmet0396

2. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–52. 10.1210/jc.2014-1498

3. Pacak K, Tella SH. Current management of metastatic pheochromocytomas and paragangliomas: Focus on systemic therapies. Endocr Rev. 2018;39(7):884–901.

4. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040–50. 10.1210/jc.2012-2356

5. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–23. 10.1038/ejhg.2010.175

6. van der Horst-Schrivers AN, Kiemeney LA, van den Berg R, Berends MJ, Wolffenbuttel BH, Kleibeuker JH, et al. The use of genetic testing in the clinical management of pheochromocytoma and paraganglioma: Current status of testing for SDHx, RET, VHL, and NF1. J Clin Endocrinol Metab. 2013;98(3):E1065–73.

7. Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: Why all patients should be offered genetic testing. Ann Surg Oncol. 2013;20(5):1444–50. 10.1245/s10434-013-2942-5

8. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67. 10.1016/S0140-6736(03)13643-4

9. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate dehydrogenase kidney cancer: An aggressive example of the Warburg effect in cancer. J Urol. 2012;188(6):2063-71. 10.1016/j.juro.2012.08.030

10. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 2014 Jan;14(2):108–19. 10.1038/nrc3633. Epub 2013 Dec 19. PMid: 24355918.

11. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Hippel-Lindau disease and pheochromocytomas. Semin Urol Oncol. 1995 May;13(2):86–94. PMid: 7540053.

12. Kessler ER, Sundaram CP. Update on the management of pheochromocytoma and paraganglioma. Curr Opin Oncol. 2021 Jan;33(1):19–25. 10.1097/CCO.0000000000000701. PMid: 33278295.

13. Lu J, Zhu L, Zheng H, Tang W. Advances in the diagnosis and treatment of pheochromocytoma and paraganglioma. Front Oncol. 2020 Dec 9;10:591947. 10.3389/fonc.2020.591947. PMid: 33363458; PMCID: PMC7744649.

14. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: Cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009 Oct 1; 69(19):3650–6. 10.1158/0008-5472.CAN-08-4005. Epub 2009 Sep 22. PMid: 19773450.

15. Hensen EF, Jansen JC, Siemers MD, Oosterwijk JC, Vriends AH, Corssmit EP, et al. The Dutch founder mutation SDHD. D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet. 2011 Jan 19(1):79–83. 10.1038/ejhg.2010.132. Epub 2010 Aug 11. PMid: 20700149; PMCID: PMC3039482.

16. Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res. 2009 Jun;41(6):405–8. 10.1055/s-0029-1202824. Epub 2009 Apr 16. PMid: 19373525.

17. Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. In: Genereviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2002 Oct 2 [updated 2018 Jul 26]. PMid: 20301715.

18. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007 Apr;92(4):4069–79. 10.1210/jc.2007-1720. Epub 2007 Mar 20. PMid: 17374714.

19. Vaidya A, Hamrahian AH, Pacak K. Pheochromocytoma: An update on genetics and management. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1–25. 10.1016/j.ecl.2013.09.002. PMid: 24582098; PMCID: PMC3960686.

20. Coco D, Leanza S. Von Hippel-Lindau Syndrome: Medical syndrome or surgical syndrome? A surgical perspective. J Kidney Cancer VHL. 2021 Dec 5;9(1):27–32. 10.15586/jkcvhl.v9i1.206. PMid: 34963877; PMCID: PMC8652351.